Sanxin Medical released its third quarterly report for 2024.
In the first three quarters of 2024, Sanxin Medical achieved operating income of 1.082 billion yuan, an increase of 16.38% year-on-year; the net profit was 183 million yuan, an increase of 20.62% year-on-year; The net profit attributable to the parent company was 168 million yuan, an increase of 18.74% year-on-year.
This work is created by Bread Finance researchers based on publicly available data and does not constitute investment advice to anyone.
Revenue increased by 16.38% year-on-year, and net profit attributable to the parent company increased by 18.74% year-on-year
In the first three quarters of 2024, Sanxin Medical's total operating income was 1.082 billion yuan, an increase of 16.38% year-on-year; the net profit attributable to the parent company was 168 million yuan, an increase of 18.74% year-on-year; The net profit attributable to the parent company after deducting non-profits was 152 million yuan, an increase of 18.84% year-on-year.
In the first three quarters of 2024, Sanxin Medical's R&D expenses were 45 million yuan, an increase of 30.8% year-on-year. The company's R&D expenses accounted for 4.13% of revenue, an increase of 0.46 percentage points year-on-year.
In a single quarter, Sanxin Medical achieved revenue of 396 million yuan in the third quarter, an increase of 11.42% quarter-on-quarter and a year-on-year increase of 13.69%. From the perspective of profitability, the company achieved a net profit attributable to the parent company of 62 million yuan in the third quarter, an increase of 17.17% month-on-month and a year-on-year increase of 18.75%.
Operating cash flow increased by 54.36% year-on-year
According to the third quarter report of 2024, the company's net operating cash flow during the period was 324 million yuan, an increase of 54.36% year-on-year from 210 million yuan in the same period last year.
Sanxin Medical's net operating cash flow in the third quarter was 187 million yuan, an increase of 68.21% year-on-year.
The inventory was 205 million yuan, and the total liabilities increased by 19.78% year-on-year
At the end of the third quarter of 2024, Sanxin Medical's total liabilities were 830 million yuan, an increase of 19.78% year-on-year.
Sanxin Medical's asset-liability ratio was 38.45%, compared with 35.69% in the same period last year, an increase of 2.76 percentage points year-on-year.
As of the end of the third quarter of 2024, the company's inventory was 205 million yuan, a year-on-year decrease of 1.78%.
(Article serial number: 1845796879397425152/EN.)
Disclaimer: This article does not constitute any investment advice to anyone. Intellectual Property Rights Statement: The intellectual property rights of Bread Finance works are owned by Shanghai Miaotan Network Technology Co., Ltd.